Annexon, Inc. (ANNX)
| Market Cap | 978.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -208.55M |
| Shares Out | 162.51M |
| EPS (ttm) | -1.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,391,474 |
| Open | 6.03 |
| Previous Close | 6.10 |
| Day's Range | 5.95 - 6.26 |
| 52-Week Range | 1.60 - 7.18 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+174.09%) |
| Earnings Date | May 11, 2026 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 174.09% from the latest price.
News
Annexon Transcript: 25th Annual Needham Virtual Healthcare Conference
2026 is set to be a milestone year, with anticipated regulatory filings and pivotal data readouts for late-stage programs in GBS, GA, and ANX1502. Vonaprument’s differentiated C1q-targeting approach in GA is advancing through a robust phase III trial, while GBS and ANX1502 programs are progressing toward key regulatory and clinical milestones.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA
Annexon Transcript: KOL event
C1q inhibition offers a novel, upstream approach to preserving vision in GA by protecting photoreceptors, with phase II data showing strong functional and structural benefits and a favorable safety profile. The phase III ARCHER II trial is fully enrolled, highly powered, and aligned with regulators, with results expected in Q4.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflamma...
Annexon Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing three late-stage programs targeting neuroinflammatory diseases, with pivotal data and regulatory filings expected in GA and GBS. Strong clinical results, a differentiated mechanism, and robust commercial planning position the pipeline for significant value creation over the next year.
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
BRISBANE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon Transcript: 44th Annual J.P. Morgan Healthcare Conference
Late-stage immunotherapy programs targeting neuroinflammatory diseases are set for pivotal milestones in 2026, including phase III data for ANX007 in geographic atrophy and regulatory filings for ANX005 in Guillain-Barré syndrome. ANX1502 advances as the first oral C1 inhibitor for autoimmune conditions.
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
Tanruprubart MAA Filed with Potential to Be the First Targeted Fast-Acting Therapy for Guillain-Barré Syndrome ( GBS); BLA Submission with U.S./European Data Planned in 2026
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from FORWARD Trial Planned in 2026 BRISBANE, Calif., Jan. 08, 2026...
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammat...
Annexon Transcript: Jefferies London Healthcare Conference 2025
The company is advancing a differentiated complement platform with late-stage programs in GBS and GA, both targeting major regulatory milestones in 2026. GBS data show strong efficacy and safety, while the GA program aims for vision preservation. An oral complement program is also progressing, with proof-of-concept data expected in 2026.
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across li...
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across li...
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing ...
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing i...
Annexon Transcript: Cantor Global Healthcare Conference 2025
The company is advancing first-in-class complement pathway inhibitors, with ANX005 showing strong phase III results in GBS and outperforming IVIG in key outcomes. Regulatory filings are on track, with EMA submission planned for Q1 2026 and pivotal data for ANX007 in GA expected next year.
Annexon Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Pioneering therapies in GBS, GA, and small molecule complement inhibition are advancing, with robust clinical data, strong regulatory engagement, and clear commercialization strategies. GBS filings are targeted for Q1 2026 in Europe, and GA phase III data is expected in 2026.
Annexon Biosciences to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devasta...
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability...
Annexon Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
At the H.C. Wainwright Ophthalmology Conference, Annexon highlighted its C1q inhibitor programs, including positive phase III results in Guillain-Barré syndrome and vision-preserving effects in dry AMD. The fully enrolled phase III ARCHER II trial for Vonaprument expects top-line data in 2026.
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation